Under construction – not a live service
Sign in
Taking people in ChinaPhase 1

Tests umbilical cord stem cells for advanced hepatitis B liver scarring

Tests umbilical cord stem cells, given by vein, in adults with liver disease.

Plain-language title generated from the registry record
Registry title: hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis

Key facts

Where
Changsha, ChinaSee the site
Phase
Phase 1

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 60 with advanced hepatitis B cirrhosis (Child-Pugh B or C) to test human umbilical cord stem cells.

Age
18 to 60 years
Sex
All sexes can join.
Disease stage
Hepatitis B cirrhosis, Child-Pugh grade B or C (score 7-12), with a Model for End-Stage Liver Disease score of 21 points or less.
Earlier treatment
No stem cell therapy in the last 6 months.
Biomarker or test result
BMI between 19 and 25 kg/m2, boundary values included.

Main reasons for not taking part

  • Poorly working vital organs such as the heart, kidney or lung
  • End-stage cirrhosis with severe complications such as hepatic encephalopathy, gastrointestinal bleeding or massive ascites
  • Infection that is not under control, such as peritonitis or pneumonia
  • Positive HIV antibody or syphilis antibody
  • Alpha fetoprotein above 400ng/mL, or liver disease not caused by hepatitis B virus

Read by machine on 12 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 60 years old?

Source: NCT03826433, who can take part

Where in China

  • Xiangya Hospital Central South UniversityChangsha, ChinaContact: ShaLing Li, doctorTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Sclnow Biotechnology Co., Ltd.
Trial code
NCT03826433
Record updated
23 April 2026
Original description
1. Evaluation the safety of using human umbilical mesenchymal stem cells to treat patients with hepatitis B cirrhosis. 2. Observe the curative effect of patients with hepatitis B cirrhosis who use human umbilical mesenchymal stem cells to treat. 3. Explore the possible mechanism of human umbilical mesenchymal stem cells to treat patients with hepatitis B cirrhosis.Read full original descriptionShow less

Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosis

1. Evaluation the safety of using human umbilical mesenchymal stem cells to treat patients with hepatitis B cirrhosis. 2. Observe the curative effect of patients with hepatitis B cirrhosis who use human umbilical mesenchymal stem cells to treat. 3. Explore the possible mechanism of human umbilical mesenchymal stem cells to treat patients with hepatitis B cirrhosis.

Inclusion: Age 18-60 years old, gender not limited, body mass index (BMI) between 19-25 kg/m2, including boundary value; The diagnosis of hepatitis B cirrhosis was in line with the 2015 American society of hepatology (AASLD) guidelines for the treatment of chronic hepatitis B, and the liver function grade was child-pugh B or child-pugh C, with a score range of 7-12 points, and Model for End-Stage Liver Disease score≤21 points; Have not received stem cell therapy in the recent 6 months; Subjects will be able to sign the informed consent in accordance with the study procedures and instructions.

Exclusion: Concomitant peritonitis, pneumonia, or other types of infection not under control; Insufficiency of vital organs, such as heart, kidney and lung; End-stage cirrhosis with severe complications, including but not limited to: hepatic encephalopathy, gastrointestinal bleeding,Severe bleeding tendency, massive ascites, etc; Have a history of severe allergic reaction or allergy to two or more kinds of food or medicine; Alpha fetoprotein>400ng/mL with primary liver cancer or without imaging evidence; Chronic liver disease and cirrhosis are caused by non-chronic hepatitis B virus infection, or other factors except chronic hepatitis B virus infection ; Patients with severe mental illness and cognitive impairment; Positive serum HIV antibody and syphilis antibody.

ClinicalTrials.gov NCT03826433